




FIG. 1A




FIG. 1B





FIG. 1C



Re-direct T cell to kill tumor cells:

- HER2-TCE engages HER2+ tumor and T cells
- T cells signal through CD3/CD28, initiating anti-tumor activities
- HER2+ tumor cells are killed by T cells

Addition of anti-CD28 provides an advantageous co-stimulatory signal:

- * Enhance duration and magnitude of the response
- * Promote T cell differentiation & survival

FIG. 1D




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 2E




FIG. 3




FIG. 4A




FIG. 4B




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D




FIG. 6E




FIG. 6F

CMV-specific CD8-Tcm
CMV Donor D, Ab at 0.2 nM




FIG. 6G

CMV-specific CD8-Tcm
CMV Donor D, Ab at 1 nM






FIG. 6H



CMV-specific CD8-Tem
CMV Donor D, Ab at 1 nM







FIG. 7A



CMV Donor E, Ab at 2 nM




FIG. 7B




FIG. 7C




FIG. 7D




FIG. 7E




FIG. 7F




FIG. 7G






FIG. 7H






FIG. 8A




FIG. 8B




FIG. 8C






FIG. 8D






FIG. 8G




FIG. 8H




FIG. 8I




FIG. 8J




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 9E




FIG. 9F




FIG. 9G




FIG. 10




FIG. 11




FIG. 12




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D




FIG. 14A

Results of Efficacy study of ZR-75- 1 Her2-CD28-CD3 dose titration




FIG. 14C

FIG. 14B




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 16A






FIG. 16B



HCC1954



HER2 Density (per cell)	IHC	HercepTest
149,601 / 33,301	3+	3+

FIG. 17A

HCC1954





FIG. 17B

BT20



HER2 Density (per cell)	IHC	HercepTest
60,829	1+	1+

FIG. 17C




FIG. 17D




FIG. 17E




FIG. 17F

	#1	#2	#3	#4	#5	#6	Control
HCC1954 (HER2-hi)	134.3	52.0	91.6	93.7	84.5	138.0	208.4
BT20 (HER2-mid)	427.6	393.9	413.6	491.4	1023.0	350.2	605.1
MDA-MB231 (HER2-lo)	761.2	471.1	665.4	1109.3	636.3	645.1	2368.7

FIG. 18A

	#1	#2	#3	#4	#5	#6	Control
OE.19 (HER2-hi)	34.3	46.5	62.8	93.2	180.6	424.4	50.4
GSU (HER2-mid)	140.4	64.2	77.6	87.3	133.0	215.2	181.9

FIG. 18B